Predictors of Long-Term Diabetes Remission After Metabolic Surgery

Journal of Gastrointestinal Surgery

Volumn 19, Issue 6, 2015, Pages 1015-1021

  Lee, Ming Hsien ^a   Lee, Wei Jei ^b   Chong, Keong ^b   Chen, Jung Chien ^b   Ser, Kong Han ^b   Lee, Yi Chih ^c   Chen, Shu Chun ^b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b MIN SHENG GENERAL HOSPITAL   (Taiwan)

^c CHING YUN UNIVERSITY   (Taiwan)

Author keywords

Metabolic surgery; Predictor; Remission; Type 2 diabetes

Indexed keywords

GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; BARIATRIC SURGERY; BLOOD; BODY MASS; COMPLICATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POSTOPERATIVE PERIOD; PROCEDURES; REMISSION; TIME FACTOR; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADULT; BARIATRIC SURGERY; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; OBESITY; POSTOPERATIVE PERIOD; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84930090280     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-015-2808-1     Document Type: Article

References (53)

1. Zimmer P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. JAMA 2013; 414:782–787.
2. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011;378:31–40.
3. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. NEJM 2008;358:2545–2559.
4. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948–958.
5. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412.
6. Hiroki Yokoyam, Okudaira M, Otani T, et al. High incidence of diabetic nephropath in early-onset Japanese NIDDM patients. Diabetes Care 1998;7:1080–1085
7. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724–1737.
8. Sjostrom L, Narbro K, Sjostrom D, et al. Effect of bariatric surgery on mortality in Swedish obese subjects. NEJM 2007;357:741–752.
9. Lee WJ, Huang MT, Wang W, et al. Bariatric surgery: Asia-Pacific perspective. Obes Surg 2005;15:751–757.
10. Dixon JB, Zimmer P, Alberti KG, Rubino F. Bariatric surgery: an IDF statement for obese type 2 diabetes. Diabet Med 2011;28:628–642.
11. Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008;299:316–323
12. Lee WJ, Chong K, Ser KH, et al. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg 2011; 146:143–148.
13. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366:1567–1576.
14. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: The diabetes surgery study randomized clinical trial. JAMA 2013;309(21):2240–2249.
15. Liang Z, Wu Q, Chen B, Yu P, Zhao H, Quyang X. Effect of laparoscopic Roux-en-Y gastric bypass for type 2 diabetes mellitus with hypertension: a randomized controlled trial. Diabetes Res Clin Prac 2013;101(1):50–56.
16. Wentworth J, Playfair J, Lavrie C, et al. Multidisciplinary diabetes care with and without bariatric surgery in overweight people: a randomized controlled trial. Lancet Diabetes Endocrinol 2014;2(7):545–52.
17. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes. N Engl J Med. 2014;370(21):2002–2013
18. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. The New England Journal of Medicine. 2004;351(26):2683–2693.
19. DiGiorgi M, Rosen DJ, Choi JJ, et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis 2010;6:249–253.
20. Chikunguwo SM, Wolfe LG, Dodson P, et al. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2010;6:254–259.
21. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26:S5–S20.
22. Buse JB, Laughlin S, Caprio S, et al. How do we define cure of diabetes? Diabetes Care 2009;32:2133–2135.
23. Matthews DR, Hosker JP, Rudensky AS, et al. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412–419.
24. Lee WJ, Yu PJ, Wang W, et al. Laparoscopic Roux-en-Y versus mini-gastric bypass for the treatment of morbid obesity: a prospective randomized controlled clinical trial. Ann Surg 2005;242:20–28
25. Ser KH, Lee WJ, Lee YC, Chen JC, Su YH, Chen SC. Experience in laparoscopic sleeve gastrectomy for morbidly obese Taiwanese: staple-line reinforcement is important for preventing leakage. Surg Endosc 2010;24(9):2253–2259.
26. Lee WJ, Hur K, Lakadawala M, Kasama K, et al. Predicting the Success of Metabolic Surgery: Age, Body Mass Index, C-peptide, and Duration Score. Surg Obes Relat Dis 2013; 9: 379–384.
27. Dixon JB, Chuang LM, Chong K, et al. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes care. 2013;36(1):20–26.
28. Dixon J, Hur KY, Lee WJ, et al. Gastric bypass in type 2 diabetes with BMI < 30: weight and weight loss have a major influence on outcomes. Diabet. Med. 2013; 30: e127–e134.
29. Maggard-Gibbons M, Maglione M, Livhits M, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: A systematic review. JAMA 2013;309:2250–2261.
30. Lebovitz HE. Metabolic surgery for type 2 diabetes with BMI < 35 Kg/m2: An endocrinologist’s perspective. Obesity Surg 2013;23:800–808.
31. Cohen RV, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diab Care 2012;35:1420–1426.
32. Lakadawala M, Shaikh S, Bandukwala S, et al. Roux-en-Y gastric bypass stands the test of time: 5-year results in low body mass index (30–35) Indian patients with type 2 diabetes mellitus. Surg Obes Relat Dis 2013;9:370–378.
33. Brethauer SA, Amino A, Ramero-Talamas H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg 2013;258:628–637.
34. Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013;23:93–102.
35. Sultan S, Gupta D, Parikh M, et al. Five-year outcomes of patients with type 2 diabetes who underwent laparoscopic adjustable gastric banding. Surg Obes Relat Dis 2010;6:373–376.
36. Johnson BL, Blackhurst DW, Latham BB, et al. Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg 2013;216:545–545.
37. Heneghan HM, Cetin D, Navaneethan SD, et al. Effects of bariatric surgery on diabetic nephropathy after 5 years of follow-up. Surg Obes Relat Dis 2013;9:7–14.
38. Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA 202;308:1122–1131.
39. Dixon JB, O’Brien PE. Selecting the optimal patient for LAP-BAND placement. Am J Surg 2002;184:17–20.
40. Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 2003;237:751–758.
41. Hamza N, Abbas MH, Darwish A, Shafeek Z, New J, Ammori BJ. Predictors of remission of type 2 diabetes mellitus after laparoscopic gastric banding and bypass. Surg Obes Relat Dis 2011;7:691–696.
42. Blackstone R, Bunt JC, Cortes MC, Sugerman HJ. Type 2 diabetes after gastric bypass: remission in five models using HbA1c, fasting blood glucose, and medication status. Surg Obes Relat Dis 2012;8:548–555.
43. Still CD, Wood GC, Benotti P, et al. A probability score for preoperative prediction of type 2 diabetes remission following RYGB surgery. Lancet Diabetes Endocrinol 2014;2:38–45.
44. Muscelli E, Mari A, Casolaro A, et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008;57:1340–1348.
45. Lee WJ, Wang W, Lee YC, et al. Effects of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI > 35 and < 35 Kg/m2. J Gastrointest Surg 2008;12:945–952.
46. Kim JW, Cheong JH, Hyung WJ, Choi SH, Noh SH. Outcome after gastrectomy in gastric cancer patients with type 2 diabetes. World J Gastroenterol. 2012;18:49–54.
47. Lee WJ, Chong K, Ser KH, et al. C-peptide Predicts the Remission of Type 2 Diabetes after Bariatric Surgery. Obesity Surgery 2012; 22:293–298.
48. Aarts EO, Janssen J, Janssen IM, Berends FJ, Telting D, de Boer H. Preoperative fasting plasma C-peptide level may help to predict diabetes outcome after gastric bypass surgery. Obes Surg 2013;23:867–873.
49. Sjostrom L. Review of the key results from the Swedish obese subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Int Med 2013;273:219–234.
50. Carrison LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Sweden obese subjects. NEJM 2012;367:2683–2693.
51. Thaler JP, Cummings DE. Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 2009;150:2518–25.
52. DePaula AL, Macedo AL, Rassi N, et al. Laparoscopic treatment of metabolic syndrome in patients with type 2 diabetes mellitus. Surg Endosc 2008; 22(12):2670–8.
53. 2 (LBMI). Obes Surg 2009;19:307–311.